<p>This combination is contraindicated in:</p>

<ul>
	<li>Patients with known hypersensitivity to levodopa or benserazide or any of the excipients.</li>
	<li>Patients receiving non-selective monoamine oxidase (MAO) inhibitors due to the risk of hypertensive crisis. However, selective MAO-B inhibitors, such as selegiline and rasagiline, or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with this combination.</li>
	<li>Patients with decompensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases with a psychotic component or closed angle glaucoma. Because levodopa may activate a malignant melanoma, this combination should not be used in patients with suspicious, undiagnosed lesions or a history of melanoma.</li>
	<li>The management of patients with intention tremor and Huntington&rsquo;s chorea.</li>
	<li>Patients less than 30 years old (skeletal development must be complete).</li>
</ul>